Stabilized radiophosphate-labeled proteins
AssigneeImmunomedics, Inc.
InventorShui-on Leung
Life of this patent
Estimating the term…
Abstract
A radiotherapeutic agent comprising a 32P or 33P radiolabeled protein selected from the group consisting of: wherein X is an targeting peptide, Y is a phosphorylation peptide, L is a flexible linker, preferably a peptide linker, and SH2 represents an SH2 domain; whereby said phosphorylation peptide is radiolabeled with 32P or 33P
Claims25
A radiotherapeutic agent comprising a 32P or 33P radiolabeled protein selected from the group consisting of:
- X-Y′-L-SH2(I);
- X-SH2-L-Y′(II);
- wherein X is a targeting peptide, Y′ is a phosphorylation peptide, L is a linker and SH2 represents an SH2 domain;
- wherein said phosphorylation peptide is radiolabeled with 32P or 33P and wherein the linker is long and flexible enough to allow the SH2 domain to make a turn and fold back on the phophorylated substrate.
A radiotherapeutic agent precursor comprising a protein selected from the group consisting of:
- X-Y-L-SH2 (I);
- X-SH2-L-Y (II);
- and
- wherein X is an targeting peptide, Y is a phosphorylation peptide, L is a linker and SH2 represents an SH2 domain, and wherein the linker is long and flexible enough to allow the SH2 domain to make a turn and fold back on the phophorylated substrate.
A method for treating a tumor or an infectious lesion in a patient comprising administering an effective amount of a radiotherapeutic agent wherein said radiotherapeutic agent comprises a 32P or 33P radiolabeled protein selected from the group consisting of:
- X-Y-L-SH2 (I);
- X-SH2-L-Y (II);
- Y-X-SH2 (III);
- and
- wherein X is a targeting peptide, Y is a phosphorylation peptide, L is a flexible linker and SH2 represents an SH2 domain;
- wherein said phosphorylation peptide is radiolabeled with 32P or 33P.
Dependencies are inferred from the claim text.